Featured Research

from universities, journals, and other organizations

Oscillations at odds in the heart

Date:
March 15, 2010
Source:
Rockefeller University Press
Summary:
Researchers show that a classical biological oscillator, the glycolytic oscillator, may increase damage to the heart during acute loss of oxygen (anoxia), and as may occur during ischemia.

Researchers in Germany show that a classical biological oscillator, the glycolytic oscillator, may increase damage to the heart during acute loss of oxygen (anoxia), and as may occur during ischemia. The study appears online March 15 in the Journal of General Physiology.

Oscillations are important in many biological processes, and life could not exist without them. They play roles in the cell cycle, the heart beat, circadian rhythms, and fertility cycles, to name a few. Although oscillations are vital for normal physiological functions, uncontrolled or irregular oscillations can have harmful effects. This may be true of glycolytic oscillations that occur during anoxia and ischemia in the heart.

Glycolytic oscillations have been studied in the past, but only in artificially induced conditions. Klaus Benndorf and his team from the University of Jena were able to create more clinically relevant conditions by using a technique that allowed a single isolated patch-clamped heart muscle cell to be imaged with fluorescent dyes during severe anoxia.

According to James Weiss and Jun-Hai Yang (UCLA) in a Commentary accompanying the paper, the next step will be to determine whether such metabolic oscillations can be detected during acute ischemia in the intact heart, and if so, whether they play a role in hastening cell death.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ganitkevich, V., V. Mattea, and K. Benndorf. Diffusion of a soluble protein, photoactivatable GFP, through a sensory cilium. J. Gen. Physiol, Feb 2010; 135: 173 - 196. DOI: 10.1085/jgp.200910322

Cite This Page:

Rockefeller University Press. "Oscillations at odds in the heart." ScienceDaily. ScienceDaily, 15 March 2010. <www.sciencedaily.com/releases/2010/03/100315103818.htm>.
Rockefeller University Press. (2010, March 15). Oscillations at odds in the heart. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/03/100315103818.htm
Rockefeller University Press. "Oscillations at odds in the heart." ScienceDaily. www.sciencedaily.com/releases/2010/03/100315103818.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins